‘Work with us’: Wealth giant’s pitch to Australian regulators

  • 📰 FinancialReview
  • ⏱ Reading Time:
  • 31 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 16%
  • Publisher: 90%

Australia Headlines News

Australia Latest News,Australia Headlines

Abrdn says it has digital tools that can help narrow Australia’s advice gap, but winning the support of regulators is proving challenging.

, which has increased sharply since the banking royal commission.

The question for investors willing to dip their toe in the water is: where to do it? Buehlmann argues that Asia and emerging markets, where Abrdn has historically been strong, could provide something of a safe haven right now, given the monetary policy pressure seen in Australia and the United States is not as prevalent.

Second, active management will matter in a period like this. Finding the right stocks – his preference is for quality companies with good balance sheets and pricing power – will be important in a world where there are plenty of bargains but alpha may be hard to find.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

...and provide ABRDN with a cash cow that all it does is rip people off...

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 2. in AU

Australia Latest News, Australia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

‘Very appealing’: US vaccine giant looks to amp up Australian trialsNovavax’s chief medical officer says the company is looking to bring more R&D to Australia, including trials of its combined coronavirus and influenza vaccine. MsEmmaK Australia please say NO MsEmmaK MsEmmaK
Source: smh - 🏆 6. / 80 Read more »

‘Very appealing’: US vaccine giant looks to amp up Australian trialsCOVID-19 vaccine maker Novavax is looking to do more clinical trials in Australia, including further research to develop its combined coronavirus and influenza vaccine. Too late. With 95% 'vaccination' rate, there will be too much interference between the effects of prior vaccines and Novavax. Besides, Pfizer needs until 2025 (at a minimum) to analyse its 'longer' term data... Will Pfizer accept contamination of its trial? TheDohertyInst A ready source of guinea pigs.
Source: theage - 🏆 8. / 77 Read more »

Working into his 70s is this business owner’s new realityTurmoil on markets has prompted some Australians approaching retirement to revise their plans and work longer.
Source: FinancialReview - 🏆 2. / 90 Read more »

Record $15trn household wealth ‘as good as it gets’Australian households increased their total wealth 1.2 per cent in the March quarter, and by 35 per cent since the start of the pandemic. on average Unfortunately it is based on the internal valued of the A$ not the external value - No quite equal to Argentina pegging their currency to the US$ but still not going well.
Source: FinancialReview - 🏆 2. / 90 Read more »

Crypto consumer safeguards expected ‘within 12 months’Caroline Malcolm, head of international policy at cryptocurrency tracking and investigations firm Chainalysis, believes Australian regulators will roll over added layers of protections for consumers in the next year.
Source: FinancialReview - 🏆 2. / 90 Read more »

January freed up for Australian Test stars to play in BBL as draft unveiledA rich overseas BBL draft will tempt the likes of Andre Russell, Kieron Pollard and Faf du Plessis, while organisers work overtime to secure top Australians danbrettig shorten the season ffs
Source: smh - 🏆 6. / 80 Read more »